BriaCell Therapeutics Corp (NASDAQ:BCTX) shares are trading higher Wednesday after the company announced the U.S. Food and Drug Administration granted Fast Track status to Bria-IMT for the treatment of metastatic breast cancer.
Bria-IMT is a cell-based immunotherapy designed to selectively destroy tumor cells without harming the normal cells.
BriaCell is currently enrolling and dosing advanced breast cancer patients in a Phase 1/2a study of Bria-IMT with Incyte's checkpoint inhibitor, retifanlimab, and its immunomodulator, epacadostat in a collaboration with Incyte. The Fast Track designation will apply to patients with metastatic breast cancer. Fast Track improves the speed and frequency of communication with the FDA.
BriaCell is a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer.
See Also: Morning Brief: Top Stories Dominating Financial Media on Wednesday, April 13
BCTX 52-Week Range: $2.81 - $12.47
According to data from Benzinga Pro, the stock was up 12.1% at $11.11 at publication time.
Photo: mohamed_hassan from Pixabay.
